orforglipron vs tirzepatide

orforglipron (S-tier) vs tirzepatide (S-tier). mechanism, trials, claims vs data, dosing literature. side-by-side reference.

orforglipron — tier S

foundayo. the first non-peptide small-molecule oral GLP-1 receptor agonist. a once-daily pill, no injection, FDA-approved april 2026 for chronic weight management.

a small molecule, not a peptide. the first non-peptide oral GLP-1 receptor agonist to reach FDA approval. eli lilly's once-daily pill, sold as foundayo.

~12.4% ATTAIN-1 wt loss · half-life supports once-daily oral dosing per the FDA-approved label; small-molecule oral absorption without the food/water restrictions of oral peptide GLP-1s · weight loss

tirzepatide — tier S

mounjaro and zepbound. GLP-1 plus GIP dual agonist. beats semaglutide head-to-head on weight loss.

the dual GLP-1/GIP agonist that beat semaglutide head-to-head. mounjaro for diabetes, zepbound for obesity, same molecule.

22.5% SURMOUNT-1 wt loss · half-life ~5 days · weight loss

at a glance

• orforglipron: tier S · ~12.4% ATTAIN-1 wt loss
• tirzepatide: tier S · 22.5% SURMOUNT-1 wt loss

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.